| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Kenneth B Lee Jr. last filed a Form 4 in June 2023, as Director at BCRX. The filings on record cover 2 companies. Kenneth B Lee Jr.'s net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Kenneth B Lee Jr. a below-average insider score of 42/100, based on 5 past trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -24.3%.
At the last filing, the largest reported position was 68,863 shares of BCRX. The BCRX filings lean toward selling, a net 1,000 shares.
Kenneth B Lee Jr. has 18 Form 4 filings on record from May 2016 to June 2023, across 2 companies: Director at Biocryst Pharmaceuticals (BCRX), 2016–2023; Director at Hyperion Defi (HYPD), 2018–2022.
The 28 reported transactions were 13 option or other derivative awards, 7 stock awards, 5 open-market purchases and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $62K and 1 sale worth about $92K.
The largest open-market purchase was 6,000 shares of HYPD at an average $5.42 on June 15, 2021, about $33K. Twelve months later HYPD was down 65%.
The only open-market sale was 6,000 shares of BCRX at an average $15.35 on September 13, 2021, about $92K. Twelve months later BCRX was down 15%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 | HYPD Hyperion Defi, Inc. | Director | Buy | 10,000 | $2.20 | $22,000.00 | +30.9% | -16.3% | +58.4% | |
| Sep 13, 2021 | BCRX Biocryst Pharmaceuticals Inc | Director | Sale+OE | 6,000 | $15.35 | $92,100.00 | -19.8% | -25.2% | -15.0% | |
| Jun 15, 2021 | HYPD Hyperion Defi, Inc. | Director | Buy | 6,000 | $5.42 | $32,512.00 | +31.0% | -17.6% | -65.3% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Director | Buy | 5,000 | $1.45 | $7,250.00 | +48.8% | - | - |